Item 2.02. Results of Operations and Financial Conditions
On January 20, 2021, Inovio Pharmaceuticals, Inc. (the "Company") filed with the
Securities and Exchange Commission ("SEC") a preliminary prospectus supplement
(the "Preliminary Prospectus Supplement") in connection with a proposed public
offering of shares of its common stock, which contained information regarding
the Company's preliminary estimates of its cash, cash equivalents and short-term
investments and shares of common stock outstanding as of December 31, 2020. The
Company preliminarily estimates that its cash, cash equivalents and short-term
investments as of December 31, 2020 was approximately $412 million and that it
had 186,851,493 shares of common stock outstanding as of December 31, 2020.
These preliminary estimates are not a comprehensive statement of the Company's
financial results for the fiscal year ended December 31, 2020 and have not been
audited, reviewed or compiled by the Company's independent registered public
accounting firm. The Company's actual cash, cash equivalents and short-term
investments and shares of common stock outstanding as of December 31, 2020 may
differ from these estimates due to the completion of the Company's year-end
closing and auditing procedures.
The information provided in this Item 2.02 of this Form 8-K shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any of the
Company's filings under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
The Preliminary Prospectus Supplement contained an updated description of
certain aspects of the Company's business, certain legal proceedings and certain
risk factors. Accordingly, the Company is filing this information with this
Current Report on Form 8-K for the purpose of supplementing and updating
disclosures contained in the Company's prior filings with the SEC, including
those discussed in the Company's most recent Annual Report on Form 10-K for the
fiscal year ended December 31, 2019, filed with the SEC on March 12, 2020, as
supplemented by the Company's subsequent filings with the SEC. The updated
disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit
No. Exhibit Description
99.1 Updated Corporate Disclosure.
104 Cover page interactive data file (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses